ClinicalTrials.gg
Status unknownNCT01245166Updated Nov 22, 2010

A Phase III Randomized, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg Plus Acarbose 50 mg Tablets) Versus Acarbose Alone in Subjects With Type 2 Diabetes Mellitus

A Phase 3 interventional study of Acarbose and Metformin/Acarbose in The Objectives of the Study is to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg, Plus Acarbose 50 mg Tablets) Thrice Daily Versus Acarbose 50 mg Thrice Daily Over 16 Weeks in and Subjects With Type 2 Diabetes Mellitus., sponsored by Lotus Pharmaceutical. Status unknown at 1 site in Taiwan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2010-11-22.

Sponsored by Lotus Pharmaceutical · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2010), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 293 studies testing metformin in Diabetes Mellitus, Type 2 — 17 open to participants now, 22 under way, 2 of them phase 3. Metformin · Diabetes Mellitus, Type 2.

Planned enrollment
87th of 287
220 · median 100
Started
2010
with 19 others
Phase 3
72 of 293
1 open now
Registered
118th of 293
by date

Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, this one is the 87th largest by planned enrollment of the 287 interventional ones that give a count, is one of 20 that started in 2010, is one of 72 in phase 3, and was the 118th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

17 of the 293 studies testing metformin in Diabetes Mellitus, Type 2 are open now, in 7 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About metformin

Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 293 studies testing metformin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Type 2 diabetes mellitus is a chronic metabolic disorder which is caused by both insulin secretion deficiency and insulin action defect. In this type of subjects, fasting hyperglycemia is the result of the elevated rate of basal hepatic glucose production, and it is coexisting with hyperinsulinemia.After a meal, the impaired control of hepatic glucose production by insulin and decreased insulin-mediated glucose uptake by muscle contributed nearly equally to postprandial hyperglycemia(Scheen, 1997). Type 2 diabetic subjects experience significant morbidity and mortality from microvascular (retinopathy, nephropathy, and neuropathy) and macrovascular (cardiovascular disease, stroke, and peripheral vascular disease) complications. The appropriate treatment and good glycemic control of diabetes is therefore important and necessary (Vaag, 2006). Evidences suggest that combination therapy using oral antidiabetic agents with different mechanisms of action may be more effective in achieving and maintaining target blood glucose level (Turner et al., 2005).There are five classes of oral antihyperglycemic agents (sulfonylureas, biguanides, α- ucosidase inhibitors, thiazolidinediones and meglitinides) currently available to improve glycemic control in subjects with type 2 diabetes, each of which works through a different mechanism of action. Metformin, a biguanide which has insulin-sensitizing properties, can be used alone or in combination with other classes of agents. Metformin is the currently the first-choice treatment in subjects with diagnosed type 2 diabetic subjects and obesity, characterized by insulin-resistance. Metformin also provides reduction of body weight and ameliorates lipid abnormalities and is thought to be related to a reduction in hepatic gluconeogenesis (Hundal \& Inzucchi, 2003).Acarbose, the α-glucosidase inhibitor, is approved for the treatment of type 2 diabetes, and first approved for prediabetes treatment (Chiasson et al., 1994; Breuer, 2003; Chiasson et al., 2002). The drug was launched worldwide as a type 2 diabetes monotherapy and combination therapy in 1990 which has proven efficacious as first-line therapy (Coniff et al., 1995) and in combination with sulfonylureas or insulin (Kelley et al., 1998). Acarbose and metformin are both associated with beneficial effects on hyperglycemia, hyperinsulinemia, body weight, and, in some studies,triglyceride levels (Krentz et al., 1994). Because these factors are part of a cluster of risk factors for cardiovascular disease, combining the two drugs may be useful. In long-term clinical studies, acarbose has shown a favorable safety profile (Hasche et al., 1999).In combination with metformin, acarbose has been shown to improve long-term glycemic control (Rosenstock et al., 1998; Halimi et al., 2000). This study was conducted as a further vestigation into the efficacy and safety of concurrent use of acarbose and metformin in type 2 diabetes mellitus subjects.Lotus Pharmaceutical Co., Ltd. intends to initiate Phase III program to investigate assess the efficacy and safety of metformin in combination with acarbose for type 2 diabetes mellitus subjects considered inadequately blood glucose control. Since combination tablet of acarbose and metformin has not yet been approved by the Taiwan DOH, this study is conducted to evaluate the efficacy and safety of combination tablet of acarbose and metformin in the treatment of type 2 diabetes mellitus subjects in Taiwan. Acarbose is chosen as an active-comparator.

03

Conditions studied

  • The Objectives of the Study is to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg
  • Plus Acarbose 50 mg Tablets) Thrice Daily Versus Acarbose 50 mg Thrice Daily Over 16 Weeks in
  • Subjects With Type 2 Diabetes Mellitus.
04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects may be included in the study only if they meet all of the following criteria:

    1. Male or female subjects aged ≥ 20 and ≤ 80 years old;
    2. Subject with type 2 diabetes mellitus;
    3. Subject with documented ≥ 7 % and ≤ 10 % within 3 months prior study and at screening;
    4. \< 35 kg/m2;
    5. Subject is willing and able to comply with study procedures and sign .

Exclusion criteria

Exclusion Criteria:

  • Subjects will be excluded from the study for any of the following reasons:

    1. Subject with type 1 diabetes or secondary diabetes;
    2. Subject with history or concurrent ketonuria or other acidosis;
    3. Subject with type 2 diabetes mellitus treated with high dose of sulfonylurea (gliclazide > 320 mg, glibenclamide > 20 mg, glimepiride > 6 mg, and glipizide > 20 mg) or with biguanides (metformin > 2000 mg), or of α-glucosidase inhibitors (acarbose > 300 mg), or with meglitinides (repaglinide > 6 mg and nateglinide > 360 mg), thiazolidinedione (rosiglitazone > 4 mg, pioglitazone > 30 mg) or with insulin;
    4. Subject with gastrointestinal disease that may interfere with absorption of the products at discretion of investigator, including but are not limited to malabsorption syndromes and gastric ulcer;
    5. Subject with kidney function impairment defined as serum creatinine > 1.5 mg/dL for male, serum creatinine > 1.4 mg/dL for female, or liver function impairment defined as > 3 X , or AST > 3 X ULN;
    6. Subject with history of drug or alcohol abuse within the past 1 year;
    7. Subject who have been diagnosed with acute myocardial infarction or cardiac failure within 6 months preceding screening;
    8. Subject with to acarbose and/or metformin products;
    9. Subject with active cancer, defined as ongoing, progressing cancer, or \< 5 years of stable disease;
    10. values \< 10 gm/dl for females or \<11 gm/dl for males;
    11. Female subject of who:

      • is lactating; or · has positive urine pregnancy test at Visit 1; or
      • refuse to adopt reliable method of during the study;
    12. Subject is to acarbose and/or metformin treatment;
    13. Subject has received any investigational agent within 28 days prior to the first dose of investigational product;
    14. Subject who have a history or evidence of a medical condition that would expose them to an undue risk of a significant adverse event during the course of the trial, including but not limited to hepatic, renal, respiratory, cardiovascular, endocrine,immune, neurological, or hematological disease as determined by the clinical judgment of the investigator.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
220 participants (estimated)

Study arms

  • Active comparator
    Acarbose

    Drug: Acarbose

  • Experimental
    Metformin/Acarbose

    Drug: Metformin/Acarbose

Interventions

  • Acarbose 50 mg, per orem, thrice daily

  • DrugMetformin/Acarbose

    Drug pages: Metformin · Acarbose

    Metformin HCl 500 mg plus Acarbose 50 mg Tablets, per orem, thrice daily

06

What researchers measure

Primary outcomes

  1. The changes from baseline in HbA1c to the end of treatment period

    Time frame: -4 weeks, 0 week, 8 weeks, 12 weeks, 16 weeks

Secondary outcomes

  1. the change from baseline to the end of treatment in FBG, PBG, lipid profiles, and body weight. The safety evaluation will include: 1) Adverse events; 2) Laboratory data; 3) Physical examination; 4) Vital signs; 5) 12- lead ECG

    Time frame: -4 weeks, 0 week, 4 weeks, 8 weeks, 12 weeks, 16 weeks

07

Study locations

1 of 1 sites recruiting
  • Taichung Veterans General Hospital
    Taichung, 40705, Taiwan
    Recruiting
08

References and documents

Publications

  • Wang JS, Huang CN, Hung YJ, Kwok CF, Sun JH, Pei D, Yang CY, Chen CC, Lin CL, Sheu WH; acarbose/metformin fixed-dose combination study investigators. Acarbose plus metformin fixed-dose combination outperforms acarbose monotherapy for type 2 diabetes. Diabetes Res Clin Pract. 2013 Oct;102(1):16-24. doi: 10.1016/j.diabres.2013.08.001. Epub 2013 Aug 15. PubMed 23993469 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Jun 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2010
First posted
Nov 22, 2010
Start
Nov 2010
Primary completionEst.
Jun 2011
CompletionEst.
Dec 2011
Last update
Nov 22, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01245166
First posted
Nov 22, 2010
Start date
Nov 2010
Primary completion
Jun 2011 (estimated)
Completion
Dec 2011 (estimated)
Last update
Nov 22, 2010

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Metformin · Acarbose

Start the discussion